Untitled Document

Exploring the Role of Non-Anthracycline Regimens in Early Breast Cancer

Exploring the Role of Non-Anthracycline Regimens in Early Breast Cancer


Discussant:
Mark Pegram, MD
University of Miami
Miami, Florida, United States
Perimenopausal Breast Cancer: What Is the Optimal Therapy?

Perimenopausal Breast Cancer: What Is the Optimal Therapy?


Discussant:
Mary Cianfrocca, DO
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois, United States
Disease Progression After Adjuvant Anthracycline and Taxane

Disease Progression After Adjuvant Anthracycline and Taxane


Discussant:

William Gradishar, MD, FACP
Robert H Lurie Comprehensive Cancer Center
Northwestern University
Chicago, Illinois, United States

Adjuvant Endocrine Therapy for a Postmenopausal Patient at Intermediate Risk of Recurrence

Adjuvant Endocrine Therapy for a Postmenopausal Patient at Intermediate Risk of Recurrence


Discussant:

Robert E. Coleman, MD, FRCP, FRCPE
Weston Park Hospital
Sheffield, United Kingdom

Current Management of Recurrent Triple-Negative Breast Cancer: What’s the Best Approach?

Current Management of Recurrent Triple-Negative Breast Cancer: What’s the Best Approach?


Discussant:

Joyce O’Shaughnessy, MD
Texas Oncology
Baylor Sammons Cancer Center
Dallas, Texas, United States

Targeted Therapy for HER2-Overexpressing Metastatic Breast Cancer

Targeted Therapy for HER2-Overexpressing Metastatic Breast Cancer


Discussant:
Kathy Miller, MD
Indiana University
Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States
The Use of Gene Expression Profiles in Node-Negative Endocrine-Responsive Early Breast Cancer

The Use of Gene Expression Profiles in Node-Negative Endocrine-Responsive Early Breast Cancer


Discussant:
Harold Burstein, MD, PhD
Dana Farber Cancer Institute
Boston, Massachusetts, United States

About prIME Oncology Cases in Breast Cancer

 
prIME Oncology invites you to participate in our prIME Cases in Breast Cancer series; a CME-certified series of 7 case studies, each with an expert perspective from internationally renowned thought leaders in breast cancer.
 
Participants will be able to vote on their preferred therapy choice(s) and will immediately be able to view the aggregate, real-time results of their peers’ choices.